Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2008-03-04
2008-03-04
Saoud, Christine J. (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S070100, C435S320100, C536S023100, C536S023500
Reexamination Certificate
active
07338788
ABSTRACT:
The present invention provides new interferon β conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4686191 (1987-08-01), Itoh et al.
patent: 4769233 (1988-09-01), Bell et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4914033 (1990-04-01), Bell et al.
patent: 4917888 (1990-04-01), Katre et al.
patent: 4966843 (1990-10-01), McCormick et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5376567 (1994-12-01), McCormick et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5545723 (1996-08-01), Goelz et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5795779 (1998-08-01), McCormick et al.
patent: 6514729 (2003-02-01), Bentzien
patent: 6531122 (2003-03-01), Pedersen et al.
patent: 7144574 (2006-12-01), Rasmussen et al.
patent: 2003/0170206 (2003-09-01), Rasmussen et al.
patent: 2003/0175240 (2003-09-01), Pedersen et al.
patent: 2004/0013644 (2004-01-01), Rasmussen et al.
patent: 083 069 (1987-09-01), None
patent: 0 287 075 (1988-10-01), None
patent: 0 370 205 (1990-05-01), None
patent: 041 313 (1990-09-01), None
patent: 229 108 (1990-12-01), None
patent: 260 350 (1992-02-01), None
patent: 0 529 300 (1993-03-01), None
patent: 287 075 (1995-01-01), None
patent: 539 300 (1996-02-01), None
patent: 593 868 (1998-04-01), None
patent: WO 95/25170 (1995-09-01), None
patent: WO 95/27502 (1995-10-01), None
patent: WO 98/35026 (1998-08-01), None
patent: WO 98/48018 (1998-10-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/55377 (1999-11-01), None
patent: WO 99/67291 (1999-12-01), None
patent: WO 00/23114 (2000-04-01), None
patent: WO 00/23472 (2000-04-01), None
patent: WO 00/26354 (2000-05-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Activity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Derwent Abstract 012152872 for WO 98/48018, a German publication cited in previous IDS Form-1449.
Derwent Abstract 009442954 for EP 539 300, a French publication cited in previous IDS Form-1449.
Fierlbeck et al., “Neutralising interferon β antibodies in melanoma patients treated with recombibant and natural interferon β”Cancer Immunol Immunother(1994) 39:263-268.
Karpusas et al., “The Structure of Human Interfereon- β: Implications for activity”CMLS54 (1998) 1203-1216.
Karpusas et al. “The crystal structure of human interferon β at 2.2 A resolution” Proc. Nat. Acad. Sci. USA (1997) 94:11813-11818.
Mayorga et al., “Antibodies to Commerically Available Interferon-Bet Molecules in Multiple Sclerosis Patients Treated with Natural Interferon-Beta”Int. Arch. Allery Immunol1999; 118:368-371.
Munschauer et al., “Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis”Clinical Therapeuticsvol. 19, No. 5, 1997 883-893.
Redlich et al., “Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping”Proc. Natl. Acad. Sci. USAvol. 88, pp. 4040-4044 May 1991.
Rudick et al., “Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis”NeurologyMay 1889, 50: 1266-1272.
Runkel et al., Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)Pharmaceutical Researchvol. 15, Nol. 4, 1998, 641-649.
Runkel et al, 1998, Jour. Biol. Chem. Difference in Activity between αand β Type I Interferons Explored by Mutational Analysis 273, No. 14, pp. 8003-8008.
Senda et al., “Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution”J. Mil. Biol.(1995) 253, 187-207.
Stewart et al, DNA Chemical Mutagenesis of Human Interferon- β: Construction, Expression inE. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations vol. 6 No. 2 1987 p. 119-128.
Tanigunchi, et al., “The nucleotide sequence of human fibroblast interferon cDNA”Gene10 (1980) 11-15.
Yong et al., “Interferon beat in the treamtent of multiple sclerosis”Neurology1998; 51: 682-689.
Apweiler et al., “On the frequency of protein glycosylation, as deducted from analysis of the SWISS-PROT database,”Biochim. Biophys. Acta1473:4-8 (1999).
O'Connell et al., “The Influence of Flanking Sequences on O-Glycosylation,”Biochemical and Biophysical Research Communications:180(2):1024-1030 (1991).
Wells et al., “Additivity of Mutational Effects in Proteins,” Biochemistry 29(37):8509-8517 (1990).
Ngo et al., “Computation Complexity, Protein Structure Prediction, and the Levinthal Paradox,”inThe Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495 (K. Merz Jr. and S. Le Grand, eds., 1994).
Andersen Kim Vilbour
Bornaes Claus
Pedersen Anders Hjelholt
Rasmussen Poul Baad
Maxygen ApS
Petithory Joanne R.
Powers Margaret A.
Saoud Christine J.
Seharaseyon Jegatheesan
LandOfFree
Interferon-β variants and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon-β variants and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon-β variants and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2784733